Format

Send to

Choose Destination

See 1 citation found by title matching your search:

J Transl Med. 2015 Jan 16;13:3. doi: 10.1186/s12967-014-0349-0.

Overcoming tumor immune evasion with an unique arbovirus.

Author information

1
PrimeVax, LLC, Garden Grove, USA. bruce.lyday@primevax.com.
2
PrimeVax, LLC, Garden Grove, USA. tony.chen@primevax.com.
3
Department of Neurosciences, Translational Neuro-Oncology Laboratories, UC San Diego, La Jolla, CA, 92093, USA. skesari@ucsd.edu.
4
Moores UCSD Cancer Center, UC San Diego, La Jolla, CA, 92093, USA. skesari@ucsd.edu.
5
Moores UCSD Cancer Center, UC San Diego, La Jolla, CA, 92093, USA. bminev@ucsd.edu.
6
Division of Neurosurgery, UC San Diego, La Jolla, CA, 92093, USA. bminev@ucsd.edu.
7
Genelux Corporation, San Diego Science Center, San Diego, CA, 92109, USA. bminev@ucsd.edu.

Abstract

Combining dendritic cell vaccination with the adjuvant effect of a strain of dengue virus may be a way to overcome known tumor immune evasion mechanisms. Dengue is unique among viruses as primary infections carry lower mortality than the common cold, but secondary infections carry significant risk of hypovolemic shock. While current immuno-therapies rely on a single axis of attack, this approach combines physiological (hyperthermic reduction of tumor perfusion), immunological (activation of effector cells of the adaptive and innate immune system), and apoptosis-inducing pathways (sTRAIL) to destroy tumor cells. The premise of using multiple mechanisms of action in synergy with a decline in the ability of the tumor cells to employ resistance methods suggests the potential of this combination approach in cancer immunotherapy.

PMID:
25592450
PMCID:
PMC4307212
DOI:
10.1186/s12967-014-0349-0
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center